最新ニュース UiPath (NYSE:PATH) 株価情報

UiPath

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

UiPath Inc

Pathfinder Bancorp Inc

PATHFINDER CELL THERAPY by Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy Inc

Pathfinder Ventures Inc

PATHFINDER VENTURES INC by PATHFINDER VENTURES INC.

Pathward Financial Inc

Mizuho analyst Siti Panigrahi maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Neutral and lowers the price target from $12 to $11.

News

Price Target

Analyst Ratings

PATH

Mizuho Maintains Neutral on UiPath, Lowers Price Target to $11

On Friday, April 11, 2025, Cathie Wood-led Ark Invest executed notable trades, shedding shares in UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), Prime Medicine Inc. (NGM: PRME), and Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>).
The PATH Trade
Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 4,256 shares of UiPath Inc. Based on the closing price of $10.87 on the day of the trade, the total value of the transaction amounts to approximately $46,280.32.
UiPath&#8217;s stock saw a slight increase of 2.26% on the day.
The PRME Trade
Prime Medicine Inc. was another company that Ark Invest decided to reduce its stake in. The ARKK fund sold 83,510 shares of PRME. With the stock closing at $1.33 on the day of the trade, the value of the sold shares is around $111,068.30.
Interestingly, PRME&#8217;s stock experienced a significant surge of 13.68% on the trade day.
See Also:<a href="https://www.benzinga.com/news/management/25/04/44774273/jpmorgan-ceo-jamie-dimon-expects-sp-500-growth-forecast-to-be-cut"> JPMorgan CEO Jamie Dimon Expects S&amp;P 500 Growth Forecast To Be Cut</a>
The RPTX Trade
Ark Invest&#8217;s Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) fund offloaded shares of Repare Therapeutics Inc. The fund sold 130,611 shares of RPTX. Given the closing price of $0.9 on the trade day, the total value of the transaction is approximately $117,549.90. The stock&#8217;s price remained unchanged on the day of the trade.
These trades come in the wake of <a href="https://www.benzinga.com/25/04/44753971/cathie-woods-thursday-plays-healthcare-ai-and-crypto-ark-scoops-up-tempus-ai-and-coinbase-stock-amid-trump-tariff-crash">Ark Invest&#8217;s previous transactions</a>, which featured prominent purchases of Tempus AI Inc and Coinbase Global Inc stocks amid a sharp market selloff triggered by economic uncertainty and a 145% China tariff announcement by the Trump administration.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/04/44774554/analyst-says-recession-chance-higher-than-50-musks-doge-cuts-to-knock-out-gdp-were-getting-closer-to-recession">Analyst Says Recession Chance Higher Than 50%, Musk&#8217;s DOGE Cuts to &#8216;Knock Out&#8217; GDP — &#8216;We&#8217;re &#8216;Getting Closer to Recession&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Markets

ARKG

ARKK

PRME

RPTX

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are trading higher on Wednesday. The company disclosed the launch of its generative AI-based UiPath Medical Record Summarization <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44715815/uipath-announces-ai-partnership-with-google-cloud-to-transform-medical-processes" rel="noreferrer noopener">agent at Google Cloud Next 2025</a>.
The agent is currently in private preview and is powered by Google Cloud Vertex AI and Gemini models.
It enables payer and provider organizations to leverage generative AI and automation for more efficient and accurate analysis of medical records.
Developed in collaboration with clinical professionals, the agent offers a clinician-level, multi-point summarization of medical documents, completing the process in minutes instead of the typical 45 minutes required by manual data entry.
Mark Geene, senior vice president of AI Products at UiPath said, &#8220;Chief medical officers, chief financial officers and CIOs at healthcare organizations are consistently under pressure to reduce costs and improve quality of care while dealing with people resource constraints. Currently, clinical and non-clinical staff must summarize large volumes of medical records, yet medical records lack standard formats and summaries meaning they vary in quality and standardization.&#8221;
The UiPath Medical Record Summarization agent cuts down on time spent on tasks like patient referral intake and utilization management reviews, saving up to 40 minutes per referral and reducing prior authorization turnaround time by up to 50%.
The agent ensures consistent, high-quality summaries with standardized sections and traceable data, enhancing the accuracy of clinical decisions and minimizing errors.
It also provides organized, structured medical records, allowing clinicians to make quicker, more informed decisions.
Last month, the company reported fourth-quarter&nbsp;revenue of $424 million, which came short of the analyst consensus of $425.36 million, while EPS of nine cents beat the <a target="_blank" href="https://www.benzinga.com/25/03/44313765/uipath-shares-drop-after-q4-revenue-miss-and-weak-q1-guidance-whats-going-on" rel="noreferrer noopener">consensus estimate of three cents</a>.
Investors can gain exposure to the stock via Global X Robotics &amp; Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>).
PATH Price Action: UiPath shares are up 12.77% at $11.13 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44311508/uipath-hit-by-slowing-arr-growth-and-deal-timing-woes-but-ai-and-cloud-spark-optimism" target="_blank" rel="noreferrer noopener">UiPath Hit By Slowing ARR Growth, Deal Timing Woes: Analyst Remains Optimistic For AI, Cloud Spark</a></li>
</ul>
Photo: Shutterstock

Mid Cap

Movers

Tech

BOTZ

UiPath Unveils AI-Powered Medical Record Summarization Solution, Significantly Cuts Processing Time

WIIM

ABTS

ADBE

ADSK

ALKT

ASAN

AVPT

BILL

BRZE

BTBT

BTDR

BTOG

CFLT

CIFR

CRWD

CVLT

CYBR

DDOG

DOCU

ESTC

FROG

FRSH

FTNT

GTLB

HUBS

INTA

INTU

KVYO

NCNO

ORCL

PANW

PEGA

QTWO

QUBT

RBRK

SEMR

SOUN

WDAY

Shares of software companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

On Friday, April 4, 2025, Cathie Wood-led Ark Invest made substantial trades involving several prominent companies including Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), CRISPR Therapeutics AG (NGM: CRSP), Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), Roblox Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>).
The COIN Trade
Ark Invest purchased shares of Coinbase Global Inc across multiple ETFs. Ark Invest&#8217;s ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) bought 12,187 shares, while the ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) funds added 54,988 and 15,982 shares, respectively.
The total value of the COIN shares bought, calculated from the last closing price of $160.55, amounts to approximately $13.5 million.
The AMZN Trade
Amazon.com Inc also saw significant buying action from Ark Invest. The ARKF, ARKK, and ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) funds bought 9,018, 25,528, and 8,408 shares, respectively.
Given Amazon&#8217;s last closing price of $171.0, the total value of the shares bought is approximately $7.4 million.
The CRSP and BEAM Trades
The ARKK fund bought 69,011 shares of CRISPR Therapeutics AG and 142,713 shares of Beam Therapeutics Inc. Based on the last closing prices of $32.65 and $15.2,7, respectively, the total value of the CRSP and BEAM shares bought is approximately $3.5 million.
The PATH Trade
Ark Invest's ARKK sold 448,505 shares of UiPath, while ARKQ sold 147,575 shares. The ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) fund sold 323,575 shares, and the ARKF fund sold 434,637 shares.
The RBLX, MELI, and RPTX Trades
Ark Invest sold shares of Roblox Corp. and MercadoLibre Inc. across various ETFs. Additionally, the ARKG fund sold 32,613 shares of Repare Therapeutics Inc, valued at approximately $32,613 based on the last closing price of $1.0.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44652222/trumps-tariffs-may-shift-us-spending-from-goods-to-services-creating-uncertainty-for-ecommerce-and-advertising-industries-analyst-warns">Tariffs To Impact End Demand: Goldman Sachs Analyst Expects Drag On Corporate Spending, Hiring</a> </li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

ETFs

AMZN

ARKF

ARKQ

ARKW

BEAM

COIN

CRSP

MELI

RBLX

Cathie Wood's Ark Invest Loads Up On Amazon Amid Over 20% Decline In A Year: Offloads UiPath, Roblox

Shares of software companies are trading lower as global markets continue to decline following President Trump's announcement of sweeping tariffs

On Thursday,&nbsp;Cathie Wood-led Ark Invest made a significant move by purchasing shares of&nbsp;Robinhood Markets Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>). This strategic investment comes as Robinhood continues to expand its platform, enhancing its financial services offerings.
The Robinhood Trade
Ark Invest purchased 36,250 shares of Robinhood on Thursday. The trade, executed through the ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), amounted to approximately $1.39 million based on Robinhood&#8217;s last closing price of $38.26. The stock corrected by over 10% amid a broader <a href="https://in.benzinga.com/government/regulations/25/04/44631916/wall-street-wipes-out-2-trillion-apple-eyes-worst-day-since-covid-19-pandemic-oil-plummets-whats-driving-markets-thursday">market slump</a> triggered by the imposition of trade tariffs by President Donald Trump. This move follows a series of investments by Ark in Robinhood.
On Wednesday, Ark purchased 6,875 shares of Robinhood through ARKK. That trade was valued at roughly $293,425. The Wood-led firm has consistently been purchasing the stock this week. On Monday, it <a href="https://www.benzinga.com/25/03/44576678/cathie-wood-defies-coreweave-ipo-slump-ark-snaps-up-3-6-million-worth-of-stock-in-nvidia-backed-company">mopped up Robinhood shares</a> worth $1.32 million, while on Tuesday it <a href="https://in.benzinga.com/25/04/44599184/cathie-woods-tuesday-bet-ark-loads-up-on-more-robinhood-stock-amid-platform-expansion">added 7,798</a> shares worth $328,764.
Robinhood is undergoing a significant transformation, as it recently launched an <a href="https://www.benzinga.com/news/25/03/44528951/robinhood-expands-into-banking-will-offer-customers-4-savings-apy-and-cash-home-delivery">integrated suite of financial services.</a> This includes the introduction of Robinhood Banking, which offers checking and savings accounts with a competitive 4% annual percentage yield. The service also provides Federal Deposit Insurance Corporation insurance coverage up to $2.5 million through Coastal Community Bank, a subsidiary of Coastal Financial Corp. This expansion aims to attract retail investors seeking more sophisticated private banking and investment solutions.
Other Key Trades:
<ul>
<li>Sold 41,130 shares of UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from the ARKF and another 302,251 shares from ARKW.</li>
<li>Sold 119,913 shares of Repare Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) from the ARKG.</li>
<li>Bought 21,209 shares of GitLab Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) through the ARKK.</li>
<li>Bought 6,222 shares of GitLab Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) through the ARKW and 21,209 shares via ARKK.</li>
</ul>
Image via Shutterstock
Read Next: 
<ul>
<li><a href="https://benzinga.com/25/04/44579139/trump-administration-reportedly-mulls-tax-hike-for-americas-wealthy-a-funding-strategy-for-other-priorities" target="_blank" rel="noreferrer noopener">Trump Reportedly Considers Raising Taxes On Ultra-Wealthy Striking Rare Common Ground With Ideological Rivals Bill Gates, Bernie Sanders</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

HOOD

Cathie Wood Doubles Down: Mops Up Another $1.39 Million Worth Of Robinhood Stock Amid Trump Tariff Dip

AUID

Shares of software companies are trading lower as markets react to President Trump's announcement of sweeping tariffs.

UiPath's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) short percent of float has fallen 10.98% since its last report. The company recently reported that it has 30.36 million shares sold short, which is 7.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>UiPath Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743014724_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UiPath has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UiPath's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, UiPath's peer group average for short interest as a percentage of float is 5.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on UiPath?

RBC Capital analyst Matthew Hedberg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and maintains $13 price target.

Reiteration

RBC Capital Reiterates Sector Perform on UiPath, Maintains $13 Price Target

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

Needham Reiterates Hold on UiPathto Hold

<a href="https://www.uipath.com/newsroom/coronis-health-enhances-healthcare-delivery-systems-through-uipath-platform" title="https://www.uipath.com/newsroom/coronis-health-enhances-healthcare-delivery-systems-through-uipath-platform">https://www.uipath.com/newsroom/coronis-health-enhances-healthcare-delivery-systems-through-uipath-platform</a>

'Coronis Health Enhances Healthcare Delivery Systems Through UiPath Platform' - UiPath

On Friday, Mar. 14, 2025, the&nbsp;Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades involving&nbsp;GitLab Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>),&nbsp;Intellia Therapeutics Inc&nbsp;(NGM: NTLA),&nbsp;Prime Medicine Inc&nbsp;(NGM: PRME),&nbsp;UiPath Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>),&nbsp;Ibotta Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>),&nbsp;Roblox Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>),&nbsp;Repare Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), and&nbsp;CareDx Inc&nbsp;(NGM: CDNA).
The PATH Trade:&nbsp;Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) funds sold shares of UiPath Inc. The ARKK fund sold 1,092,269 shares, while the ARKW fund sold 158,650 shares.
With the stock closing at $10.88, the total value of the sold shares was approximately $13.61 million.
The RBLX Trade:&nbsp;Ark Invest&#8217;s ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) and ARKW funds sold shares of Roblox Corp. The ARKF fund sold 10,057 shares, while the ARKW fund sold 28,700 shares.
With the stock closing at $56.51, the total value of the sold shares was approximately $2.19 million.
The GTLB Trade:&nbsp;Ark Invest&#8217;s ARKK fund bought 81,543 shares of GitLab Inc, with the stock closing at $52.08. This translated to an investment of approximately $4.24 million.
The ARKW fund also purchased 22,610 shares of GitLab Inc, amounting to an investment of around $1.18 million.
The NTLA Trade:&nbsp;The ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds of Ark Invest bought shares of Intellia Therapeutics Inc. The ARKG fund acquired 11,276 shares, while the ARKK fund purchased 56,244 shares.
With the stock closing at $9.14, the total investment was approximately $0.62 million.
The PRME Trade:&nbsp;Ark Invest&#8217;s ARKK fund sold 46,026 shares of Prime Medicine Inc. The stock closed at $1.79, making the total value of the sold shares around $82,386.
The IBTA Trade:&nbsp;Ark Invest&#8217;s ARKF and ARKW funds bought shares of Ibotta Inc. The ARKF fund acquired 10,967 shares, while the ARKW fund purchased 68,234 shares.
With the stock closing at $37.87, the total investment was approximately $2.99 million.
The RPTX Trade:&nbsp;Ark Invest&#8217;s ARKG fund sold 53,449 shares of Repare Therapeutics Inc.
The stock closed at $1.1, making the total value of the sold shares around $58,794.
The CDNA Trade:&nbsp;Ark Invest&#8217;s ARKG fund sold 47,153 shares of CareDx Inc. The stock closed at $18.9, making the total value of the sold shares around $891,191.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44345022/ray-dalio-has-a-chilling-warning-for-president-trump-debt-crisis-is-imminent-and-an-issue-of-paramount-importance">Ray Dalio Has A Chilling Warning For President Trump: Debt Crisis Is Imminent, And An Issue Of &#8216;Paramount Importance&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

CDNA

IBTA

NTLA

Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta

AMBA

AMPG

ANET

APLD

ARQQ

ASNS

AXTI

BNZI

CDNS

CRDO

CSAI

ERIC

FCUV

GRRR

INFA

IONQ

LITE

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MCHP

MNDY

MOBBW

MSFT

MVIS

NVTS

OSIS

PCOR

PONY

RCAT

RGTI

SITM

SMCI

SNOW

SPSC

TRMB

VERI

VNET

WOLF

WRAP

WULF

YAAS

Shares of companies in the broader technology sector are trading higher. The sector may be rising as the overall market rebounds after falling recently on tariff concerns.

BMO Capital analyst Keith Bachman maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Market Perform and lowers the price target from $16 to $11.5.

BMO Capital Maintains Market Perform on UiPath, Lowers Price Target to $11.5

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Extreme Fear&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Dow Jones index falling more than 500 points during the session following the release of economic data.
U.S. producer prices came in unchanged in February from January compared to a revised 0.6% increase in the previous period and versus estimates of a 0.3% gain. U.S. initial jobless claims declined by 2,000 to 220,000 in the first week of March, compared to market estimates of 225,000.
On Thursday, U.S. President Donald Trump threatened to impose a 200% tariff on European wine and spirits imports unless the EU eliminates its 50% tariff on U.S. whiskey.
Shares of Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) gained around 7% on Thursday after the company reported better-than-expected fourth-quarter sales results. UiPath Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares dipped around 16% after the company reported a fourth-quarter revenue miss and issued first-quarter revenue guidance below estimates.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, real estate and communication services stocks recording biggest losses on Thursday. However, utilities stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 537 points to 40,813.57 on Thursday. The S&amp;P 500 fell 1.39% to 5,521.52, while the Nasdaq Composite dipped 1.96% at 17,303.01 during Thursday's session.
Investors are awaiting earnings results from Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) and The Buckle, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) today.
At a current reading of 14.8, the index remained in the &#8220;Extreme Fear&#8221; zone on Thursday, versus a prior reading of 20.7.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

Earnings

Pre-Market Outlook

Dow Tumbles Over 500 Points On Tariff Threats; Fear Continues To Grip Markets, Fear & Greed Index Remains In 'Extreme Fear' Zone

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are trading lower Thursday after the company reported fourth-quarter revenue and issued lower-than-expected revenue guidance <a href="https://www.benzinga.com/25/03/44311508/uipath-hit-by-slowing-arr-growth-and-deal-timing-woes-but-ai-and-cloud-spark-optimism">for the first quarter. </a>
What To Know: Despite beating earnings estimates with quarterly earnings of nine cents per share versus the expected three cents, UiPath&#8217;s revenue came in at $424 million, just short of the analyst consensus of $425.36 million. This increased from $405.25 million in the same quarter last year.
CEO Daniel Dines highlighted that fiscal 2025 was one of the company&#8217;s most innovative years, citing the launch of new AI-driven automation products, including Autopilot, Agent Builder, Agentic Orchestration and Agentic Testing. UiPath also announced the acquisition of Peak, an AI-native company, although no specific financial terms were disclosed.
Despite these developments, investors reacted negatively to the company's first-quarter revenue guidance, which is projected between $330 million and $335 million, significantly below the $368.08 million consensus estimate. 
PATH Price Action: Uipath shares were down 14.0% at $10.18 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-1024x534.png" alt="" class="wp-image-823745" style="width:456px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07.png 1514w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44311699/wall-streets-downward-slide-returns-gold-breaks-records-intel-skyrockets-on-ceo-appointment-whats-driving-markets-thursday">Wall Street&#8217;s Downward Slide Returns, Gold Breaks Records, Intel Skyrockets On CEO Appointment: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image Via Shutterstock.

UiPath Shares Drop After Q4 Revenue Miss And Weak Q1 Guidance: What's Going On?

UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) stock price declined Thursday after the company reported a <a href="https://www.benzinga.com/news/earnings/25/03/44290549/uipath-shares-plunge-after-q4-revenues-miss-weak-q1-guidance" target="_blank" rel="noreferrer noopener">fourth-quarter revenue</a> miss.
The New York-based company issued first-quarter revenue guidance below estimates on Wednesday.It reported largely disappointing fourth-quarter results, predominantly driven by deal delays in its US Fed segment.
These delays also drove initial fiscal 2026 guidance below estimates due to additional uncertainty of deal timing for this vertical.
Also Read: <a href="https://www.benzinga.com/25/03/44209166/cathie-wood-led-ark-invest-roblox-roku-uipath-as-markets-take-a-dip" target="_blank" rel="noreferrer noopener">Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip</a>
Needham analyst Scott Berg reiterated UiPath <a href="https://www.benzinga.com/quote/PATH/analyst-ratings" target="_blank" rel="noreferrer noopener">with a Hold</a>.
Total revenues of $423.6 million were below his $425.3 million estimate. Berg noted currency exchange rate fluctuations had a negative $2 million impact on revenues. When adjusting a similar effect to ARR, the net new ARR of $59 million was ~$5 million below guidance.
On the optimistic side, customers are now using 3k of UiPath&#8217;s Agents, which the analyst noted as a strong initial interest in Agentic innovations. The analyst would expect the small pilots to expand substantially in the second half of 2026.
UiPath also noted stronger-than-expected growth of its Cloud model, with ARR up more than 50%, which Berg said was a catalyst to incremental AI adoption since much of the innovation is better served in the Cloud. The fourth-quarter revenue and adjusted EPS were $423.6 million and $0.26, compared to the analyst&#8217;s $425.3 million and $0.19 estimates.
Total revenue increased by 4.5%, subscription revenue grew by 22.3%, and license revenue went down by 10.2%.
ARR grew 13.8% to $1.67 billion, a deceleration from the 16.6% growth in the third quarter and the 21.6% growth seen last year. Net new ARR of $59 million represents a 31% decline.
The customer count of 10,750 decreased by 140 sequentially and was down 0.7% compared to last year.
To date, customers have deployed over 3,000 agents on the UiPath platform. Overall, AI has a 20% customer attach rate, with a greater than 85% attach rate for customers with over $1 million in ARR.
UiPath&#8217;s acquisition of AI-native company Peak has a relatively small impact on fiscal 2026 financials, given that it falls under the regulatory threshold on financial disclosure.
UiPath is facing elevated levels of uncertainty driven by public sector dynamics, macro volatility, and currency exchange rate fluctuations. Revenue growth guidance of 6.8% to $1.525 billion—$1.530 billion missed the consensus $1.584 billion forecast.
Price Action: PATH stock is down 14.54% at $10.11 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44305045/archer-taps-palantirs-ai-to-supercharge-electric-aircraft-production-and-flight-tech" target="_blank" rel="noreferrer noopener">Archer Taps Palantir&#8217;s AI to Supercharge Electric Aircraft Production and Flight Tech</a></li>
</ul>
Image: Courtesy of UiPath, Inc.

UiPath Hit By Slowing ARR Growth, Deal Timing Woes: Analyst Remains Optimistic For AI, Cloud Spark

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are <a href="https://www.benzinga.com/quote/PATH/analyst-ratings" target="_blank" rel="noreferrer noopener">trading lower on Thursday.</a>
The company released its fourth-quarter results<a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44290549/uipath-shares-plunge-after-q4-revenues-miss-weak-q1-guidance" rel="noreferrer noopener"> after Wednesday&#8217;s closing bell.</a> Here&#8217;s a look at the key figures&nbsp;from the report.&nbsp;&nbsp;
UiPath reported quarterly earnings of&nbsp;nine&nbsp;cents per share, which beat the analyst consensus estimate of&nbsp;three&nbsp;cents.
Quarterly revenue of $424 million missed the analyst consensus estimate of&nbsp;$425.36 million&nbsp;and is an&nbsp;increase over revenue of&nbsp;$405.25 million from&nbsp;the same period last year.
Scotia Bank analyst Nick Altmann reiterated the Sector Perform rating on the stock, lowering the price forecast to $12 from $15.
Altmann expresses caution about rewarding UiPath for its margin improvements, given that medium-term concerns persist regarding the company&#8217;s ability to effectively transition into AI, with growth continuing to face pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/technicals/25/03/44308689/stock-of-the-day-is-dollar-tree-set-to-move-higher" rel="noreferrer noopener">Stock Of The Day: Is Dollar Tree Set To Move Higher? (Updated)</a>
While the analyst acknowledges the company&#8217;s 9% ARR growth forecast, which aligns with its guidance, and a second-half weighted NNARR guide, Altmann highlights the stock is likely to remain range-bound.
The analyst notes the public sector represents UiPath&#8217;s third-largest vertical, although management refrains from specifying the exact mix. Given the ongoing macroeconomic pressures, management is adopting a more cautious approach to its guidance.
Additionally, the analyst highlights a dip in NRR, which fell to 110% from the previous 113%.
The low-end segment continues to face challenges, as evidenced by a decline in net adds, with a drop of 40 this quarter compared to a smaller loss of 20 in the prior quarter.
Despite these concerns, the analyst acknowledges margins remain a positive aspect, with record operating margins of 32%, and the FY26 guidance of approximately 18%, which is above the consensus of 15%. 
The primary focus for the company continues to be stabilizing growth, which has yet to materialize, Altmann adds.
PATH Price Action: UiPath shares are trading lower by 14.38% to $10.15 at publication Thursday.
Read Next:
• <a href="https://www.benzinga.com/government/regulations/25/03/44301835/trump-threatens-200-tariff-on-european-wine-alcohol-stocks-react" target="_blank" rel="noreferrer noopener">Trump Threatens 200% Tariff On European Wine, Alcohol Stocks React</a>

Photo: Courtesy of UiPath, Inc.

Analyst Color

General

UiPath Stock Down: Faces Caution Despite Margin Gains, Analyst Doubtful About Company's AI Transition Capability

RBC Capital analyst Matthew Hedberg maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and lowers the price target from $16 to $13.

RBC Capital Maintains Sector Perform on UiPath, Lowers Price Target to $13

Press Releases

UiPath Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results Conference Call

UiPath Expands Healthcare Automation with New Global Professional Services Capabilities for Electronic Medical Records Platform

UiPath Acquires Peak to Launch Vertically Specialized Agents within its Agentic Automation Platform

UiPath Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

How Agents are Accelerating Enterprise-Wide Transformation: UiPath to Unveil Latest Agentic Automation Solutions at Agentic AI Summit

UiPath Offers Complimentary Trial of Automation Cloud Public Sector to Assist U.S. Government Agencies' Efficiency Initiatives

UiPath Launches Test Cloud to Bring AI Agents to Software Testing

UiPath Announces AI Partnership with Google Cloud to Transform Medical Processes

Veho Adds Veteran Finance Leader Alex Estevez to its Board

UiPath Recognized as a Leader in the Everest Group Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2025

Comments

UiPath

ニュース

最新ニュース UiPath (NYSE:PATH) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル